A sampling method for quantifying the information content of IASI channels

There is a vast amount of information about the atmosphere available from instruments on board satellites. One example is the Infrared Atmospheric Sounding Interferometer (IASI) instrument, which measures radiances emitted from Earth’s atmosphere and surface in 8461 channels. It is difficult to transmit, store, and assimilate such a large amount of data. A practical solution to this has been to select a subset of a few hundred channels based on those that contain the most useful information. Different measures of information content for objective channel selection have been suggested for application to variational data assimilation. These include mutual information and the degrees of freedom for signal. To date, the calculation of these measures of information content has been based on the linear theory that is at the heart of operational variational data assimilation. However, the retrieval of information about the atmosphere from the satellite radiances can be highly nonlinear. Here, a sampling method for calculating the mutual information that is free from assumptions about the linearity of the relationship between the observed radiances and the state variables is examined. It is found that large linearization errors can indeed lead to large discrepancies in the value of mutual information. How this new estimate of information content can be used in channel selection is addressed, with particular attention given to the efficiency of the new method. It is anticipated that accounting for the nonlinearity in the channel selection will be beneficial when using nonlinear data assimilation methods currently in development

Ongoing outbreak of dengue serotype 3 in Solomon Islands, January to May 2013

Introduction\ud \ud In January 2013, clinicians in Honiara, Solomon Islands noted several patients presenting with dengue-like illness. Serum from three cases tested positive for dengue by rapid diagnostic test. Subsequent increases in cases were reported, and the outbreak was confirmed as being dengue serotype-3 by further laboratory tests. This report describes the ongoing outbreak investigation, findings and response. \ud \ud Methods\ud \ud Enhanced dengue surveillance was implemented in the capital, Honiara, and in the provinces. This included training health staff on dengue case definitions, data collection and reporting. Vector surveillance was also conducted. \ud \ud Results\ud \ud From 3 January to 15 May 2013, 5254 cases of suspected dengue were reported (101.8 per 10 000 population), including 401 hospitalizations and six deaths. The median age of cases was 20 years (range zero to 90), and 86% were reported from Honiara. Both Aedes aegyti and Aedes albopictus were identified in Honiara. Outbreak response measures included clinical training seminars, vector control activities, implementation of diagnostic and case management protocols and a public communication campaign. \ud \ud Discussion\ud \ud This was the first large dengue outbreak documented in Solomon Islands. Factors that may have contributed to this outbreak include a largely susceptible population, the presence of a highly efficient dengue vector in Honiara, a high-density human population with numerous breeding sites and favourable weather conditions for mosquito proliferation. Although the number of cases has plateaued since 1 April, continued enhanced nationwide surveillance and response activities are necessary

Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy

PURPOSE: The purpose of this study is to summarize the effectiveness and safety of metreleptin in patients with congenital or acquired generalized lipodystrophy. METHODS: Patients (n = 66) aged ≥6 months had lipodystrophy, low circulating leptin, and ≥1 metabolic abnormality (diabetes mellitus, insulin resistance, or hypertriglyceridemia). Metreleptin dose (once or twice daily) was titrated to a mean dose of 0.10 mg/kg/day with a maximum of 0.24 mg/kg/day. Means and changes from baseline to month 12 were assessed for glycated hemoglobin (HbA1c), fasting triglycerides (TGs), and fasting plasma glucose (FPG). Additional assessments included the proportions of patients achieving target decreases in HbA1c or fasting TGs at months 4, 12, and 36, medication changes, and estimates of liver size. Treatment-emergent adverse events (TEAEs) were recorded. RESULTS: Significant mean reductions from baseline were seen at month 12 for HbA1c (-2.2%, n = 59) and FPG (-3.0 mmol/L, n = 59) and mean percent change in fasting TGs (-32.1%, n = 57) (all p ≤ 0.001). Reductions from baseline over time in these parameters were also significant at month 36 (all p < 0.001, n = 14). At month 4, 34.8% of patients had a ≥1% reduction in HbA1c and 62.5% had a ≥30% reduction in fasting TGs; at month 12, 80% of patients had a ≥1% decrease in HbA1c or ≥30% decrease in TGs, and 66% had a decrease of ≥2% in HbA1c or ≥40% decrease in TGs. Of those on medications, 41%, 22%, and 24% discontinued insulin, oral antidiabetic medications, or lipid-lowering medications, respectively. Mean decrease in liver volume at month 12 was 33.8% (p < 0.001, n = 12). Most TEAEs were of mild/moderate severity. CONCLUSIONS: In patients with generalized lipodystrophy, long-term treatment with metreleptin was well tolerated and resulted in sustained improvements in hypertriglyceridemia, glycemic control, and liver volume